Last reviewed · How we verify
NCT07581834
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
Phase 2 trial testing Dalpiciclib 125mg in Breast Diseases in 2,000 participants. Currently enrolling.
Quick facts
| Lead sponsor | Fujian Cancer Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Enrollment | 2,000 |
| Start date | 21 January 2026 |
| Estimated completion | 30 June 2032 |
Drugs / interventions tested
- Dalpiciclib 125mg — full drug profile →
- Dalpiciclib 100mg — full drug profile →
- Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen — full drug profile →
Conditions studied
- Breast Diseases — all drugs for Breast Diseases →
- Breast Neoplasms — all drugs for Breast Neoplasms →
- Dalpiciclib — all drugs for Dalpiciclib →
- Endocrine Breast Diseases — all drugs for Endocrine Breast Diseases →
Sponsor
Fujian Cancer Hospital
Who can join
Eligibility, any sex, with Breast Diseases or Breast Neoplasms.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07581834
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dalpiciclib 125mg
Trials testing the same drug.
- NCT07285382 — Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced · Phase 2 · recruiting
Other recruiting trials for Breast Diseases
Currently open trials in the same condition.
- NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
- NCT07038369 — A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · Phase 1 · active not recruiting
- NCT07010939 — A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients · recruiting
- NCT06780176 — A Study of Breast Cancer Risk Factors and Outcomes of People in Florida · recruiting
- NCT06805812 — Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormon · recruiting
Other Fujian Cancer Hospital trials
Trials by the same sponsor.
- NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
- NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
- NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07581834 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
- Last refreshed: recently
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07581834.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing